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management in FNAIT is weekly IVIG administration, with or without the addition of corticosteroids.
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INTRODUCTION
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) may lead to severe bleeding complications such as intracranial hemorrhage, in the fetus or newborn. Thrombocytopenia is caused by maternal alloantibodies against human platelet (PLT) antigens (HPA) resulting from maternal alloimmunization after exposure to paternally derived antigens on fetal PLTs. Most commonly involved are HPA-1a alloantibodies, which are responsible for approximately 80% of FNAIT cases. 1, 2 Not only do these maternal alloantibodies cause destruction and inhibit the production of fetal PLTs, they are also thought to affect vascular integrity, angiogenesis, resulting in an increased risk of intracranial and extracranial bleeding complications in fetuses and neonates and potentially intrauterine and perinatal death. [3] [4] [5] [6] In the absence of population-based screening programs, the diagnosis of FNAIT is usually made after an incidental finding of neonatal thrombocytopenia or because of bleeding complications ranging from bruising or petechiae to intracranial hemorrhage in the fetus or newborn.
Consequently, with an estimated recurrence rate of 79% of severe bleeding complications, the current challenge is to determine the best management strategy of subsequent pregnancies in women with a history of FNAIT with the goal of preventing these complications and avoiding maternal toxicities. 7 To avoid unnecessary interventions and anxiety, paternal genotyping should always be performed for the HPA involved in the preceding FNAIT. In case of paternal heterozygosity, maternal-fetal incompatibility should be determined either using amniocentesis or assessing cell-free fetal DNA, when HPA-1a is involved.
One of the first prenatal treatment strategies was ultrasound-guided fetal blood sampling (FBS) and intrauterine platelet transfusion (IUPT). 8 This technique, used for the treatment of fetal anemia, was applied to fetuses with thrombocytopenia and involved the transfusion of PLTs.
For personal use only. on November 1, 2017 . by guest www.bloodjournal.org From Cordocentesis in the presence of thrombocytopenia may however lead to fetal bradycardia, tamponade of the cord and bleeding complications in the fetus including exsanguination. In addition, given the short life span of transfused PLTs, transfusions are needed regularly, increasing the overall risk of fetal loss. 9 The first non-invasive treatment, maternal infusion of intravenous immunoglobulin (IVIG) was reported in 1988, after which IVIG rapidly gained ground as a standard antenatal treatment strategy for FNAIT as have corticosteroids. 10 Prolonged use of IVIG and corticosteroids during pregnancy are associated with adverse effects as well.
Although the side effects of IVIG are usually mild, hemolytic anemia, renal failure, aseptic meningitis and thrombotic complications may occur. 11, 12 Corticosteroids are associated with hypertension and diabetes. Both agents can affect the quality of life of patients.
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No international consensus on the optimal antenatal management of FNAIT exists and numerous strategies, non-invasive as well as invasive, are applied in different centers specialized in antenatal therapy. Since FNAIT is a rare disease, systematically reviewing the literature to determine the evidence to support antenatal treatment options can inform practice. Hence, we performed a systematic review of all available literature on antenatal management strategies, to be used to inform and assist in the development of guidelines.
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METHODS

Data Sources
This review was performed according to the PRISMA guidelines. 13 With the assistance of a medical research library specialist, an electronic search strategy was developed, and applied to databases Medline, EMBASE and Cochrane Library from 1946 to December 2015 (Appendix).
Reference lists were cross-checked for relevant citations.
Study Selection and data extraction
Citations were reviewed by two reviewers to identify studies that met the following inclusion criteria: 1) original study, 2) included five or more pregnant women with pregnancies at risk for FNAIT or fetuses/neonates diagnosed with FNAIT, 3) treated with either IVIG, steroids or IUPT, 4) included any of the following outcomes (intracranial hemorrhage and fetal/neonatal PLT count) and 5) published in the English language. In case of disagreement, the full report was retrieved and independent assessment was repeated. Disagreements for inclusion were resolved by consensus. For articles that were published more than once and contained the same FNAIT population, only the study with the largest number of women and the most complete data extraction was included. Data extraction was performed by two authors according to a predetermined standardized format of study characteristics, outcome data and complications of interventions (Table 1) .
Risk of bias was assessed according to The Cochrane Collaboration's tool. 14 for randomized studies, and Newcastle-Ottawa Scale (NOS) 15 for nonrandomized studies. The NOS is based on three parameters: selection, comparability and outcome (Table 2) . For the parameter selection, we assessed if the exposed cohort was representable for the FNAIT population 
Data Analysis
Due to considerable methodological heterogeneity of the studies, a descriptive review of all included studies was performed rather than a meta-analysis. In 2011 a Cochrane review of part of the included RCTs was performed by Rayment et al, 16 who also did not pool data.
RESULTS
Study selection and characteristics
Our search strategy retrieved a total of 4692 single records that were screened for title and abstract, resulting in 93 full articles to be assessed for eligibility. Of those 26 studies describing antenatal interventions in FNAIT were included (Figure 1) The overall quality of the RCTs was considered adequate, with the lack of blinding presenting the highest risk of bias (Table 2 ). Comparing or pooling data from the nonrandomized cohort studies included in this review was hampered by differences in patient selection, in particular HPA type and severity of disease in the previous affected siblings 21, 24 . In addition, relevant data were lacking in several studies, such as exclusion of ICH by ultrasound before starting treatment 35 and outcome data for all treatment arms (Table 2) .
Antenatal management
IVIG and corticosteroids
Of the 26 studies, 17 had a treatment arm with IVIG alone, 19,20,22- 
FBS / IUPT
Fetal blood sampling was employed in 24 of the 26 studies. In 16 of these studies, FBS was combined with IUPTs. Five studies included a study arm with IUPT as sole treatment. 25, 27, 28, 38, 42 IUPT in combination with IVIG was used in three studies. 21, 33, 40 The remainder of IUPTs were performed in addition to a maternal therapy strategy of IVIG and/or steroids. [17] [18] [19] 21, 25, 28, 29, 39, 42 One study reported FBS and PLT transfusion in all fetuses prior to delivery. 21 Three studies did not report the number of IUPTs performed for their study groups.
22,29,34
Risk stratification
Four studies stratified by risk group and altered interventions based on risk. 19 Table 1 ).
Perinatal outcome
Intracranial Hemorrhage
All but one study described the occurrence of ICH for all study arms. 29 In the 25 studies in which ICH was described, of the 839 pregnancies, a total of 24 ICHs were observed (3%). Seven of these occurred before treatment was started and one occurred in a group where no treatment was provided. Four ICHs were described by Heaver et al 41 as part of a large retrospective analysis of patients with suspected FNAIT investigated at a reference laboratory. Unfortunately, no additional information on previously affected pregnancies or on the patients themselves was provided. Of the remaining 12 patients, five were described by Bussel et al, 19 who reported different strategies of IVIG treatment in a high risk population (all siblings suffered from ICH).
Three ICHs (two grade III-IV hemorrhages resulting in fetal demise and one grade I hemorrhage) occurred after receiving 1g/kg/week IVIG and 1mg/kg/day prednisone, the fourth one was a grade II-III perinatal hemorrhage after delivery at 24 weeks' gestation and the last one was a grade I hemorrhage, both after a combination of 2g/kg/week IVIG with 1mg/kg/day prednisone. 
Mortality
Two studies did not report mortality rates. 22, 29 In the 24 remaining studies there was an overall mortality rate of 4% (30/821), of these 17 were related to a FBS/IUPT (53%) and seven were due to ICH (22%). In six fetuses/neonates the cause could not be determined. Ghevaert et al 41 described a fetal loss due to acute amnionitis at 16 weeks' gestation (not related to treatment) and Murphy et al 40 report a fetal loss after a severe fall of the mother on icy pavement.
Neonatal PLT Count
Twenty studies reported neonatal PLT counts. Of the other six studies, one study reported the fetal PLT counts before pre-delivery IUPT, 17 /L) compared to 17 women treated with 0.5g/kg/week (104 x10 9 /L).
Treatment-related complications
Of 24 studies in which FBS was performed with or without IUPT, two studies reported no procedure-related complications and 12 studies reported a total of 53 complications with a frequency ranging from 3 to 39% per treated pregnancy (Table 3) . One study reported complications in more detail elsewhere. , 20, 43 Overall, the proportion of treated cases with complications due to either FBS or IUPT was 11% (54 complications in 497 treated pregnancies). The most frequently described complication was the performance of an emergency cesarean section, mainly due to fetal distress (persisting bradycardia or fetal decelerations), of which approximately half resulted in a delivery before 34 weeks' gestation. Fourteen of the 54 complications resulted in a fetal or neonatal death (26%).
Of the 26 studies that used either IVIG or corticosteroids, 11 reported the side effects of the treatment. The most commonly reported side effect of dexamethasone treatment was the occurrence of oligohydramnios. Headache and rash were the most frequently reported side effects of IVIG treatment, leading to discontinuing of the treatment in only one patient.
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DISCUSSION
Main findings
A non-invasive management approach in pregnancies complicated by FNAIT was found to be equally effective as compared to IUPT in preventing fetal and neonatal bleeding due to thrombocytopenia. Our analysis revealed a relatively high complication rate of antenatal management by fetal blood sampling and IUPT, with a frequency of complications of 11%, and one in three of these leading to fetal or neonatal loss. The most common non-invasive treatment administered to pregnant women was IVIG, primarily in a weekly dose of 1 g/kg. IVIG only had a 98.7% success rate for preventing ICH (4 ICHs occurred in 315 pregnancies). 16, 17, 19-24,26-32, 34,35 This is consistent with the 97.3% found in the Cochrane analysis reported by Rayment et al 16 ,
that included 37 pregnancies treated with IVIG only. However, none of the studies were powered to detect a significant difference in bleeding outcomes.
Strengths and limitations
Besides the obvious lack of randomized studies with an adequate control group (placebo or no treatment), the main limitation of our review is the heterogeneity of the extracted data from the primary studies. Although neonatal outcomes are generally well reported and appear quite homogenous, the crux of the heterogeneity is the diversity of study designs. First, there is an extensive variation in treatment strategies used, especially in different combinations. For example, Sainio et al 42 described 15 women treated with 6 different strategies (IVIG only, IVIG and steroids, IVIG and IUPT, IVIG and steroids and IUPT, as well as weekly IUPT or FBS only). Secondly, the dosage of specific treatments differed considerably, e.g., prednisone was prescribed as 0.5 to 1mg/kg/day as well as 10 mg, 20 mg, 30 mg and 60 mg per day. The interval and duration of therapeutic strategies also differed considerably between studies. For example, mean duration of IVIG treatment varied from 2 weeks 18,23 to 22 weeks. 19 Additionally, in three of the four RCTs, treatment intensification was applied to increase fetal PLT counts, which could have led to underestimation of the difference between treatment arms when comparing neonatal PLT counts. 20, 35, 37 Lastly, there is a great variability in the risk of ICH, when determined by the proportion of siblings with ICH not only between studies, but also between study arms.
The two most commonly used endpoints for studies are ICH and neonatal PLT counts.
Whereas antenatal strategies target the prevention of bleeding complications in fetuses and neonates, preferably mortality and long-term neurodevelopmental impairment should be the gold standard outcomes. As these outcomes are rare, accordingly most studies are not powered to detect significant differences between treatment strategies and must resort to using PLT counts as surrogate outcome measurements.
In this regard, there appears to be a correlation between PLT count and risk of bleeding, but this does not appear to be a linear relationship. 41 Although the neonatal PLT count appears to be a logical and best available surrogate outcome in evaluating antenatal treatment strategies, this parameter has limitations. Comparing treatment modalities based on mean or median PLT counts may therefore show some effect, but may not be meaningful clinically. 44 In addition, very low PLT counts were often found in fetuses or neonates without any bleeding. Although it is unclear to what extent animal studies can be used for understanding pathophysiology in humans, there is increasing evidence suggesting impairment of angiogenesis and endothelial integrity as a possible cause of increased bleeding tendency, leading to the assumption that thrombocytopenia not being the sole cause of bleeding complications in FNAIT. 3, 45, 46 Our systematic review was designed to evaluate the effect of antenatal treatment options on neonatal outcome including neonatal PLT count, ICH and mortality, but it did not facilitate any conclusions on the need for centralized care, the optimal timing or mode of delivery; nor Ultimately, to our knowledge this is the first systematically performed review considering all available evidence, randomized as well as non-randomized studies. Despite the size and heterogeneity of the studies limiting the strength of this evidence, we used predefined outcome measures of all available evidence on antenatal management in pregnancies complicated by FNAIT.
Interpretation
This review suggests that non-invasive treatment strategies are safe and effective options for the antenatal management of pregnancies complicated by FNAIT, with a lower risk of severe complications compared to FBS and/or IUPT. The gestational age at which to start antenatal IVIG treatment in FNAIT has, however, not been well defined. It is reasonable to consider the severity of the disease in previous pregnancies when making treatment decisions. An earlier start of IVIG treatment will not necessarily result in a linear increase in the amount of IgG transported to the fetus. 47 The amount of IgG that traverses the placenta depends on gestational age (with the greatest placental transport taking place in the third trimester), the IgG subclass, maternal IgG levels, and placental integrity.
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In cohort analyses performed by Bussel et al 19 The use of IVIG in pregnancies at risk for FNAIT is still off-label and the possible immunostimulative or immunosuppressive effect of exposing the maturing fetal immune system to IVIG has not been adequately addressed. One cohort study by Radder et al, 18 attempted to address this by examining the neurodevelopmental outcome of 50 children, at a median age of 5 years, of which 37 were exposed to IVIG during fetal life. A higher incidence of otorhinolaryngological and hearing disability in the group that did not receive IVIG was found.
IgG, IgG subclass, IgA and IgM levels were comparable between groups. A trend was found between high plasma IgE levels and in utero IVIG exposure, nonetheless no difference in eczema or allergies was observed between the two groups. Although, based on this small cohort study, in utero exposure to IVIG seems to have no clinically apparent adverse effects in early childhood, further immunological research with a larger group of patients is needed to fully answer this question.
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The benefit of adding corticosteroids to IVIG is unclear. One study found improvement in PLT counts (defined as a PLT>25 x 10(9)/L at second sampling, an increase by >10 x 10(9)/L compared to the first sampling, or PLT>40 x 10(9)/L that was not decreased by >10 x 10(9)/L). 16, 35 The remaining eight studies comparing treatment with IVIG to IVIG with steroids did not show significant differences in the PLT count, ICH or mortality. 19, 20, 22, 24, 32, [35] [36] [37] More data from randomized studies comparing IVIG to IVIG with steroids including an adequate control group are needed to reach any firm conclusions.
To achieve a major improvement in the treatment and prevention of FNAIT, physicians need to be able to prevent index cases, a strategy that was proven to be highly successful in hemolytic disease of the fetus and newborn, caused by the red cell counterpart of FNAIT. In order to do so, population-based screening programs are needed, to identify first pregnancies at risk in time to start effective antenatal prophylaxis or treatment.
CONCLUSION
This article represents a systematic review on the effectiveness of different antenatal treatment strategies in pregnancies complicated by FNAIT, aiming to prevent ICH and bleeding-related fetal/neonatal losses. Our summary provides the best available evidence that suggests that the optimal approach is a non-invasive approach, involving weekly administration of IVIG, with or without the addition corticosteroids. Regarding the optimal dose and start of the treatment, there are insufficient data to recommend a specific gestational age or specific dose. However, the data support the treatment of high-risk pregnancies (i.e. sibling suffered from ICH) with 1g/kg/week IVIG, started between 12 and 20 weeks' gestation. For standard risk pregnancies (no sibling that has suffered from ICH) the data support starting treatment between 20 and 24 weeks' gestation, and to use IVIG 1g/kg/week with or without steroids. Additional data, especially a reliable biomarker of severity in a patient known to be affected, might allow the use of a lower dose IVIG (i.e. 0.5g/kg/week) or alternatively higher dose IVIG (i.e. 2 g/kg/week) with or without corticosteroids, depending upon severity.
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